Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Making progress through molecular attacks on cancer.

C L Sawyers1

  • 1Howard Hughes Medical Institute, Department of Medicine, UCLA, Los Angeles, California 90095, USA.

Cold Spring Harbor Symposia on Quantitative Biology
|July 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2007
Same author

Research on resistance to cancer drug Gleevec.

Science (New York, N.Y.)·2001
Same author

Chronic myelogenous leukemia.

Hematology. American Society of Hematology. Education Program·2001
Same author

Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Cancer treatment in the STI571 era: what will change?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same journal

Functional and Mechanistic Interplay of Host and Viral Alternative Splicing Regulation during Influenza Infection.

Cold Spring Harbor symposia on quantitative biology·2020
Same journal

Myriad RNAs and RNA-Binding Proteins Control Cell Functions, Explain Diseases, and Guide New Therapies.

Cold Spring Harbor symposia on quantitative biology·2020
Same journal

Small RNA Function in Plants: From Chromatin to the Next Generation.

Cold Spring Harbor symposia on quantitative biology·2020
Same journal

U1 snRNP Telescripting Roles in Transcription and Its Mechanism.

Cold Spring Harbor symposia on quantitative biology·2020
Same journal

The THO Complex as a Paradigm for the Prevention of Cotranscriptional R-Loops.

Cold Spring Harbor symposia on quantitative biology·2020
Same journal

Biophysical Properties of HP1-Mediated Heterochromatin.

Cold Spring Harbor symposia on quantitative biology·2020
See all related articles

Kinase inhibitors have transformed chronic myeloid leukemia (CML) treatment. Future cancer therapies may use serum protein biomarkers to personalize treatment and track responses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Kinase inhibitor therapy has shown significant success in treating chronic myeloid leukemia (CML).
  • The approval of imatinib/Gleevec for CML has highlighted the importance of molecularly targeted cancer therapies.
  • Clinical deployment of these targeted agents presents unique challenges.

Purpose of the Study:

  • To review recent advancements in CML treatment.
  • To explore early applications of kinase inhibitor therapy in other cancers like glioblastoma.
  • To propose a future vision for cancer biomarker analysis in serum for personalized therapy.

Main Methods:

  • Review of recent clinical events and therapeutic applications in CML.
  • Examination of early kinase inhibitor therapy applications in other malignancies.

Related Experiment Videos

  • Conceptual proposal for serum tumor protein analysis.

    • Main Results:

    • Kinase inhibitors are effective in CML, validating molecularly targeted therapy.
    • Early applications in glioblastoma show potential for kinase inhibitors beyond CML.
    • Serum protein analysis offers a novel approach for tracking cancer features.

    Conclusions:

    • Molecularly targeted therapies, like kinase inhibitors, are revolutionizing cancer treatment.
    • Analysis of serum tumor proteins could enable personalized cancer therapy selection and response monitoring.
    • Cancer biomarker science has the potential to transform clinical trials and drug evaluation.